Quote this publication Share Print

FORSTEO

-
Opinions on drugs - Posted on Sep 23 2009

Reason for request

Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the new indication of treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk of fracture.

-


Actual benefit

Important

The actual benefit of this proprietary drug is substantial.


Improvement in actual benefit

IV (mineur)

In view of the available data, the Committee considers that FORSTEO will provide a minor improvement in actual benefit (IAB IV) in the treatment of glucocorticoid-induced osteoporosis in women and men at high risk of fracture with at least two vertebral fractures.


Contact Us

Évaluation des médicaments

See also

All our publication